The U.S. Food and Drug Administration has approved an Abbreviated New Drug Application (ANDA) numbered ANDA076850 for a terconazole vaginal suppository.
The product, marketed by Fougera Pharms, is a 80 mg terconazole suppository intended for vaginal administration. The submission was an original (ORIG) filing and received approval on July 12, 2006.
FDA records indicate the product’s marketing status is listed as discontinued.
法规动态2026年9月22日•1 分钟阅读
FDA Approves ANDA076850 for Terconazole Vaginal Suppository
FDA granted approval (ANDA076850) for Fougera Pharms' terconazole 80 mg vaginal suppository, now listed as discontinued.
由 PharmaCountry 团队整理 · 来源： FDA.gov
评分
(0)
(0)
(0)
(0)
(0)
留下您的评分